Terms: = Lymphoma AND DEK, D6S231E, 7913, ENSG00000124795, P35659
9 results:
1.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of dek Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells.
Tian X; Zhu Z; Wang G; Xu J; Liang A; Zhang W
Dis Markers; 2022; 2022():9312971. PubMed ID: 35769815
[TBL] [Abstract] [Full Text] [Related]
3. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan.
Mehta J; Wang H; Fryzek JP; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Oct; 55(10):2368-74. PubMed ID: 24450579
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence.
Verma SC; Cai Q; Kreider E; Lu J; Robertson ES
PLoS One; 2013; 8(9):e74662. PubMed ID: 24040311
[TBL] [Abstract] [Full Text] [Related]
5. Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation.
Chen X; Liang S; Zheng W; Liao Z; Shang T; Ma W
BMC Genomics; 2008 Jul; 9():322. PubMed ID: 18605998
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocation in hematologic malignancies.
Huang M; Li C; Liang H; Zhou J; Deng J; Liu W
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):661-3. PubMed ID: 17357482
[TBL] [Abstract] [Full Text] [Related]
7. Aberrant expression of HOXA9, dek, CBL and CSF1R in acute myeloid leukemia.
Casas S; Nagy B; Elonen E; AventÃn A; Larramendy ML; Sierra J; Ruutu T; Knuutila S
Leuk Lymphoma; 2003 Nov; 44(11):1935-41. PubMed ID: 14738146
[TBL] [Abstract] [Full Text] [Related]
8. [Allogeneic peripheral stem cell transplantation (PBSCT) for hematological malignancies].
Wu B; Sun J; Meng F
Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):420-3. PubMed ID: 11721423
[TBL] [Abstract] [Full Text] [Related]
9. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review.
Potter MN; Cross NC; van Dongen JJ; Saglio G; Oakhill A; Bartram CR; Goldman JM
Leukemia; 1993 Aug; 7(8):1302-14. PubMed ID: 8350633
[TBL] [Abstract] [Full Text] [Related]
